KYMR·Kymera Therapeutics Inc.
KYMR|Analyst Targets
KYMR|Insider Trading
KYMR|Fundamentals
KYMR|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $-1.27 | - | - |
| Q3'25 | $-0.78 | $-0.94 | -20.3% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $3M | - | - |
| Q3'25 | - | $3M | - |
KYMR|Monthly Returns
Market Data
KYMR Stock Snapshot
- Market cap
- 8.96B
- Day range
- $106.52 – $112.06
- News sentiment
- 63/100 · Bullish
- Analyst target
- $139.35 (+30.6%)
- Consensus
- Buy · 32 analysts
The setup on Kymera Therapeutics Inc. is patient: consolidation, not accumulation or distribution. Company-specific news dominates here; sector-level flows matter less than for larger names.
Behaviour On Record
What KYMR's own history says about today's numbers
- Realized volatility (21d)
- 39.0% 8th pct
- Below its peak
- -12.9%
- vs 200-day average
- +20.1%
- Up days (1y)
- 52%
Kymera Therapeutics Inc. is currently running 39.0% annualised volatility over the last 21 sessions. Measured against KYMR's own 6 years of daily returns rather than a market-wide average, that is the 8th percentile — unusually subdued by its own history, against a typical reading of 64.8%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
KYMR is trading -12.9% below its running peak. Across 5 full years on file, its median worst-drawdown-in-a-year was -63.6%, and the deepest was -78.7% in 2022. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.
Price sits +20.1% from its 200-day moving average. Against every other day in its history, that gap ranks at the 64th percentile — a somewhat wider gap than its own norm. Over the past year KYMR closed higher on 52% of sessions, and it is currently 3 sessions into a rising streak.
On October specifically: over 6 years of records, KYMR finished the month higher 3 of 6 times, with a median return of +6.1% and an average of +10.8%. Its strongest month historically has been November at +18.0% on average, its weakest May at -11.6%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: KYMR has opened more than 2% away from the prior close in 262 of 1,540 sessions (17.0% of the time), with the largest gaps running +23.0% and -12.1%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
All figures computed from 1,541 daily closes between 2020-08-21 and 2026-10-09, split-adjusted, recomputed daily. Percentiles are against KYMR's own 6-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of KYMR's sector?
Kymera Therapeutics Inc. sits in the Health Care sector, currently ranked 4th of 12 GICS sectors by relative-strength rotation score (improving). Within its narrower Biotechnology industry group, KYMR ranks 13th of 15 tracked industries, lagging.
- Sector rank
- #4 of 12
- Sector state
- Improving
- Sector rotation score
- 73
- Industry rank
- #13 of 15
Analyst Rating Changes
Are analysts turning bullish or bearish on KYMR?
Raymond James most recently initiated coverage on Kymera Therapeutics Inc. to Outperform on Oct 9, 2026 with a price target of $140. Over the last 90 days, coverage has run 1 upgrade against 0 downgrades, a net bullish lean.
- Latest action
- Raymond James — Outperform
- 90-day upgrades
- 1
- 90-day downgrades
- 0
- Net rating momentum
- +1
ETF holders
ETFs holding KYMR
News Sentiment Analysis
Sentiment gathered from recent headlines
Recent News Coverage
Most recent articles, ranked by recency (click to expand).
Technical Analysis
Real-time indicators across multiple timeframes
| Manager | Trend | Shares Held | % of Co. | Position Value | Filed |
|---|---|---|---|---|---|
| FMR LLC (Fidelity) | ▲ Buy | 12,349,256 | 14.71% | $1.42B | 2026-08-13 |
| BlackRock, Inc. | ▲ Buy | 5,538,210 | 6.60% | $635.07M | 2026-08-07 |
| Vanguard Group Inc | ▲ Buy | 6,267,644 | 7.46% | $487.69M | 2026-01-29 |
| Wellington Management Group LLP | ▼ Sell | 3,675,028 | 4.38% | $421.42M | 2026-08-14 |
| Geode Capital Management, LLC | ▲ Buy | 1,816,331 | 2.16% | $208.32M | 2026-08-12 |
| Capital Research Global Investors | ▼ Sell | 1,388,881 | 1.65% | $159.26M | 2026-08-12 |
| Goldman Sachs Group Inc | ▲ Buy | 1,187,333 | 1.41% | $136.15M | 2026-08-14 |
| Norges Bank | ▲ Buy | 757,246 | 0.90% | $86.83M | 2026-08-12 |
| AllianceBernstein L.P. | ▲ Buy | 981,521 | 1.17% | $81.75M | 2026-08-14 |
| Northern Trust Corp | ▲ Buy | 581,907 | 0.69% | $66.73M | 2026-08-13 |
| Bank of America Corp | ▲ Buy | 378,286 | 0.45% | $43.38M | 2026-08-14 |
| Two Sigma Investments, LP | ▲ Buy | 371,374 | 0.44% | $42.59M | 2026-08-14 |
| Adage Capital Partners GP, L.L.C. | ▼ Sell | 200,000 | 0.24% | $22.93M | 2026-08-14 |
| Morgan Stanley | ▼ Sell | 194,843 | 0.23% | $22.34M | 2026-08-13 |
| Marshall Wace, LLP | ▲ Buy | 167,517 | 0.20% | $19.21M | 2026-08-13 |
| Citadel Advisors LLC | ▼ Sell | 111,555 | 0.13% | $12.79M | 2026-09-02 |
| JPMorgan Chase & Co | ▼ Sell | 113,062 | 0.13% | $12.63M | 2026-08-12 |
| Squarepoint Ops LLC | ▲ Buy | 97,189 | 0.12% | $11.14M | 2026-08-14 |
| Citigroup Inc | ▲ Buy | 77,784 | 0.09% | $8.92M | 2026-08-03 |
| Wells Fargo & Company | ▲ Buy | 72,160 | 0.09% | $8.27M | 2026-08-14 |
| Invesco Ltd. | ▼ Sell | 60,813 | 0.07% | $6.97M | 2026-08-14 |
| Prudential Financial Inc | ▲ Buy | 19,290 | 0.02% | $2.21M | 2026-08-12 |
| Man Group plc | ▲ Buy | 19,085 | 0.02% | $2.19M | 2026-08-14 |
| Janus Henderson Group plc | • Hold | 21,058 | 0.03% | $1.75M | 2026-05-18 |
| Fisher Asset Management, LLC | ▲ New | 12,732 | 0.02% | $1.46M | 2026-08-04 |